Bioavailability of Disulfiram and Metformin in Glioblastomas (INSIDE)
Drug Level and Investigation of Novel Substances Indicated Downstream Effect in Glioblastoma
Sponsor: Sahlgrenska University Hospital
Terminated
Problems with including patients
Other terminated trials from Sahlgrenska University Hospital
Listed as NCT03151772, this EARLY_PHASE1 trial focuses on Glioblastoma and remains terminated or withdrawn. Sponsored by Sahlgrenska University Hospital, it has been updated 12 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated EARLY_PHASE1
-
Mar 2025 — Sep 2025 [monthly]
Terminated EARLY_PHASE1
-
Feb 2025 — Mar 2025 [monthly]
Terminated EARLY_PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Terminated EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated EARLY_PHASE1
▶ Show 7 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Terminated EARLY_PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Terminated EARLY_PHASE1
Status: Recruiting → Terminated
-
May 2019 — Oct 2020 [monthly]
Recruiting EARLY_PHASE1
-
Jun 2018 — May 2019 [monthly]
Recruiting EARLY_PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2017 — Mar 2018 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Jun 2017 — Oct 2017 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sahlgrenska University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .